ConductScience.org, home

Paper37675271

Blueprint to hepatitis B elimination in China: A modelling analysis of clinical strategies.

Li R and 11 others. JHEP Rep, 2023. Cited by 20 papers, by iCite.

Cite this record

ConductScience Library. Blueprint to hepatitis B elimination in China: A modelling analysis of clinical strategies. Papers, record 37675271. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37675271

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Blueprint to hepatitis B elimination in China: A modelling analysis of clinical strategies.
PubMed
Journal
JHEP Rep
PubMed
Year
2023
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
20
iCite
Relative citation ratio, by iCite
2.3
iCite
Revised in PubMed
2025-05-30
PubMed

Authors12

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Li RRui
2Shen MMingwang
3Ong JJJason J
4Cui FFuqiang
5Hu WWenyi
6Chan PPolin
7Zou ZZhuoru
8Su SShu
9Liu HHangting
10Zhang LLei
11Seto WKWai-Kay
12Wong WCWWilliam C W

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
001World Health OrganizationInternationalPubMed

Source PubMed

Download CSV of grants

References35

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
126563120Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.Hepatol Int2016https://conductscience.org/library/papers/26563120PubMed
227615026Interventions to optimise the care continuum for chronic viral hepatitis: a systematic review and meta-analyses.Lancet Infect Dis2016https://conductscience.org/library/papers/27615026PubMed
316530509Predicting cirrhosis risk based on the level of circulating hepatitis B viral load.Gastroenterology2006https://conductscience.org/library/papers/16530509PubMed
425164003The global burden of liver disease: the major impact of China.Hepatology2014https://conductscience.org/library/papers/25164003PubMed
534642494Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: a phase 2 randomized controlled trial.Nat Med2021https://conductscience.org/library/papers/34642494PubMed
635738290Global, regional, and national burden of hepatitis B, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019.Lancet Gastroenterol Hepatol2022https://conductscience.org/library/papers/35738290PubMed
730992636Countdown to 2030: eliminating hepatitis B disease, China.Bull World Health Organ2019https://conductscience.org/library/papers/30992636PubMed
825530442Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.Lancet2015https://conductscience.org/library/papers/25530442PubMed
916391218Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.JAMA2006https://conductscience.org/library/papers/16391218PubMed
1026725905The prognosis and management of inactive HBV carriers.Liver Int2016https://conductscience.org/library/papers/26725905PubMed
1124954675Hepatitis B virus infection.Lancet2014https://conductscience.org/library/papers/24954675PubMed
1235063115Cost-effectiveness of universal screening for chronic hepatitis B virus infection in China: an economic evaluation.Lancet Glob Health2022https://conductscience.org/library/papers/35063115PubMed
1326566246Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis.Hepatology2016https://conductscience.org/library/papers/26566246PubMed
1433658732Progress towards elimination of mother-to-child transmission of hepatitis B virus infection in China: a modelling analysis.Bull World Health Organ2021https://conductscience.org/library/papers/33658732PubMed
1534711822The impact of the timely birth dose vaccine on the global elimination of hepatitis B.Nat Commun2021https://conductscience.org/library/papers/34711822PubMed
1632255486Investment Case for a Comprehensive Package of Interventions Against Hepatitis B in China: Applied Modeling to Help National Strategy Planning.Clin Infect Dis2021https://conductscience.org/library/papers/32255486PubMed
1734590058Changing clinical care cascade of patients with chronic hepatitis B in Beijing, China.Lancet Reg Health West Pac2021https://conductscience.org/library/papers/34590058PubMed
1829072546Socioeconomic inequality in Hepatitis B vaccination of rural adults in China.Hum Vaccin Immunother2018https://conductscience.org/library/papers/29072546PubMed
1929307467Hepatocellular carcinoma.Lancet2018https://conductscience.org/library/papers/29307467PubMed
2029877316Hepatitis B virus infection.Nat Rev Dis Primers2018https://conductscience.org/library/papers/29877316PubMed

See all 35 referencesDownload CSV of references

Cited by16

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 20 citations.

PMIDTitleJournalYearIn PapersSource
42337522Forecasting monthly hepatitis B cases in China: a nationwide comparative study based on surveillance data.BMC Public Health2026https://conductscience.org/library/papers/42337522PubMed
42328238Expert Consensus on the Prevention and Treatment of Chronic Hepatitis B in Children.Infect Dis Immun2024https://conductscience.org/library/papers/42328238PubMed
41127124Feasibility of eliminating adult hepatitis B in Guangdong by 2030: A modeling study.Infect Dis Model2026https://conductscience.org/library/papers/41127124PubMed
41035085Critical analysis of the liver cancer policies and programs in China: implications for international liver cancer control.Glob Health Res Policy2025https://conductscience.org/library/papers/41035085PubMed
40937078Epidemiology, Achievements, and Challenges in the Elimination of Hepatitis B in China.J Clin Transl Hepatol2025https://conductscience.org/library/papers/40937078PubMed
40487768Dynamic predicting hepatitis B surface antigen decline rate during treatment for patients with chronic hepatitis B.Infect Dis Model2025https://conductscience.org/library/papers/40487768PubMed
40127642
Besifovir: a viable option for long-term disease control in chronic hepatitis B: Editorial on "Switching to besifovir in patients with chronic hepatitis B receiving tenofovir disoproxil fumarate: A randomized trial".
Clin Mol Hepatol2026https://conductscience.org/library/papers/40127642PubMed
40104634Modeling hepatitis B-related deaths in China to achieve the WHO's impact target.Infect Dis Model2025https://conductscience.org/library/papers/40104634PubMed
40044428[Recent advances in epidemiology, prevention and treatment of hepatitis B in China].Zhonghua Gan Zang Bing Za Zhi2025https://conductscience.org/library/papers/40044428PubMed
39961977Expanding treatment indications in chronic hepatitis B: Should we treat all patients?Hepatol Int2025https://conductscience.org/library/papers/39961977PubMed
39957746Outcome of bariatric surgery in patients with unexpected liver cirrhosis: A multicenter study from China.Liver Res2024https://conductscience.org/library/papers/39957746PubMed
39767809Correlation Between Clinical Indicators and Liver Pathology in Children with Chronic Hepatitis B.Biomedicines2024https://conductscience.org/library/papers/39767809PubMed
39069723Correspondence to editorial on "Core indicators related to the elimination of hepatitis B and C virus infection in South Korea: A nationwide study".Clin Mol Hepatol2024https://conductscience.org/library/papers/39069723PubMed
38858193[Research progress on clinical antiviral treatment of chronic hepatitis B in children].Zhonghua Gan Zang Bing Za Zhi2024https://conductscience.org/library/papers/38858193PubMed
38393523The History of Controlling and Treating Infectious Diseases in Ancient China.Curr Med Sci2024https://conductscience.org/library/papers/38393523PubMed
38313234Antiviral treatment standards for hepatitis B: An urgent need for expansion.World J Gastroenterol2024https://conductscience.org/library/papers/38313234PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/37675271

GET https://conductscience.org/api/papers/v1/37675271/references?page=2